These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29975516)

  • 1. Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring.
    Guo J; Collins S; Miller WT; Rizzo RC
    Biochemistry; 2018 Aug; 57(32):4934-4951. PubMed ID: 29975516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2.
    Ahmed M; Sadek MM; Abouzid KA; Wang F
    J Mol Graph Model; 2013 Jul; 44():220-31. PubMed ID: 23911931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
    Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
    J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach.
    Alrumaihi F
    J Biomol Struct Dyn; 2024 Aug; 42(12):6269-6279. PubMed ID: 37424103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
    Yu X; Wang T; Lou Y; Li Y
    Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational analyses of curcuminoid analogs against kinase domain of HER2.
    Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
    BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for lead discovery: application of footprint similarity targeting HIVgp41.
    Holden PM; Allen WJ; Gochin M; Rizzo RC
    Bioorg Med Chem; 2014 Jan; 22(1):651-61. PubMed ID: 24315195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mutationally activated HER2.
    Collins SJ; Guo J; Rizzo RC; Miller WT
    Chem Biol Drug Des; 2023 Jan; 101(1):87-102. PubMed ID: 36029027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach.
    Langella E; Calce E; Saviano M; De Luca S
    Mol Biosyst; 2016 Jun; 12(7):2159-67. PubMed ID: 27113673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
    Awale M; Mohan CG
    J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer.
    Li J; Wang H; Li J; Bao J; Wu C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27376283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
    Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
    J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.